Business
Endonovo Therapeutics Announces Second Quarter Results
Endonovo Therapeutics Announces Second Quarter Results.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\nLOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), today announces financial and operating results for the second quarter ended June 30, 2019.\n Alan Collier, Endonovo’s chief executive officer, stated, “I am pleased to announce we have executed the business plan and strategy we implemented after acquiring the PEMF assets and technology in December 2017, and I am additionally excited to announce the results we attained throughout the first six months of this year. Our sales network in 2018 included two distributors and several independent sales representatives throughout the United States, which began our sales and marketing efforts for SofPulse®, ultimately leading to our revenues. Throughout 2019 we expanded our team of independent sales representatives, began our marketing launch into the U.S. hospitals and we are focusing on expanding nationally.” Key Financial Highlights: Revenues for the three months ended June 30, 2019, were $62,729, as compared to $12,854 for the same period last year. Gross profits were $33,156, as compared to $12,304 for the same period last year.Revenues for the six months ended June 30, 2019, were $107,681, as compared to $19,826 for the same period last year. Gross profits were $70,397, as compared to $19,276 for the same period last year. Key Business Highlights: Received Notice of Allowance from the United States Patent and Trademark Office for another patent.Expanded SofPulse® commercialization.Provided update on liver study.Signed two distribution agreements for national distribution of Sofpulse® Electroceutical™Enrollment of first patient in clinical study at the University of New Mexico for treating traumatic brain injury using Electroceutical™ therapy.Announced feasibility study results for use of Electroceutical therapy in reducing proteinuria in chronic kidney disease patientsAnnounced positive results in critical limb ischemia study using noninvasive medical device.Provided preclinical data demonstrating that Immunotronics™ reduced infarct size and inhibited fibrosis following myocardial infarction.Announced first commercial sales for SofPulse® Wearable Electroceutical for post-operative pain and edema In December 2017, Endonovo announce...